BrightPath Biotherapeutics Co.Ltd. (4594) AI Stock Analysis

• Market Cap: ¥9.02B
• Dividend Yield: N/A
• Average Volume (3M): 13.99M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: 1254.76%
• EPS Growth: 33.94%
• Country: JP
• Employees: 42
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -2.59
• Shares Outstanding: 111,391,300
• 10 Day Avg. Volume: 21,635,670
• 30 Day Avg. Volume: 13,986,493
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥77.00
• Price Target Upside: -4.94% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: ¥77.00 ▼(-4.94% Downside)

BrightPath Biotherapeutics' overall stock score is driven by technical analysis indicating positive momentum, despite significant financial challenges. The company's strong equity base and low leverage offer some support, but persistent losses and negative cash flow raise sustainability concerns. The negative P/E ratio and lack of dividend yield further detract from its attractiveness as a valuation play.

BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model

Company Description

BrightPath Biotherapeutics Co., Ltd. (4594) is a biotechnology company focused on the development and commercialization of innovative biotherapeutics. The company operates primarily in the healthcare and biotechnology sectors, with a core emphasis on developing novel immunotherapies for the treatment of cancer and other serious diseases. BrightPath's product pipeline includes proprietary therapeutic candidates designed to harness the body's immune system to combat malignancies, aiming to provide effective and targeted treatment solutions.

How the Company Makes Money

BrightPath Biotherapeutics generates revenue primarily through the development, licensing, and commercialization of its biotherapeutic products. The company earns money by advancing its drug candidates through clinical trials and, upon successful approval, commercializing these therapies in collaboration with healthcare providers or pharmaceutical companies. Additionally, BrightPath engages in strategic partnerships and collaborations with other biotech and pharmaceutical firms, which may include licensing agreements, research and development collaborations, and milestone payments. These partnerships not only provide funding but also enhance the company's capabilities in bringing its therapies to market. Revenue is also derived from potential upfront payments, royalties, and sales of approved therapies, contributing significantly to the company's earnings.

BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview

Summary

BrightPath Biotherapeutics is facing significant financial challenges, with ongoing negative EBIT, EBITDA, and net income figures. While the company has a strong equity base and low leverage, persistent losses and negative cash flow are concerning for operational sustainability.

Income Statement

BrightPath Biotherapeutics has been experiencing significant challenges with consistent negative EBIT, EBITDA, and net income figures over the years. Despite a sharp increase in total revenue from 2024 to 2025, the company is still operating at a loss. Gross profit margin improved in 2025, but the net profit margin remains deeply negative, indicating ongoing operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's equity ratio is strong, indicating a robust equity base relative to total assets. However, the company has been consistently operating with net losses, which could affect equity over time. The debt-to-equity ratio is low, reflecting minimal leverage and a conservative capital structure, which is a positive aspect. However, persistent losses could threaten the long-term sustainability of this structure.

Cash Flow

BrightPath Biotherapeutics has a negative free cash flow, which is concerning for its liquidity and operational funding. Operating cash flow is also negative, indicating that the company is not generating sufficient cash from its core operations to cover expenses. The reliance on financing cash flow to bridge cash deficits suggests potential sustainability issues if the trend persists.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	118.00K	1.13M	72.00K	5.28M	15.41M	2.50M
Gross Profit	-511.00K	1.10M	-341.00K	3.38M	12.09M	1.36M
EBITDA	-1.20B	-1.15B	-1.17B	-1.47B	-1.45B	-1.65B
Net Income	-1.21B	-1.15B	-1.17B	-1.49B	-1.48B	-1.72B
Balance Sheet
Total Assets	1.43B	1.12B	1.23B	1.70B	2.77B	3.75B
Cash, Cash Equivalents and Short-Term Investments	1.30B	810.47M	1.06B	1.53B	2.31B	3.27B
Total Debt	500.00M	25.00M	112.50M	0.00	87.50M	0.00
Total Liabilities	655.82M	195.62M	251.27M	133.91M	239.73M	211.79M
Stockholders Equity	772.75M	924.99M	978.99M	1.57B	2.53B	3.54B
Cash Flow
Free Cash Flow	8.98M	-1.25B	-1.16B	-1.21B	-1.53B	-1.81B
Operating Cash Flow	8.98M	-1.25B	-1.16B	-1.20B	-1.51B	-1.77B
Investing Cash Flow	0.00	-1.37M	-7.65M	-1.76M	-17.57M	-36.21M
Financing Cash Flow	0.00	1.00B	690.96M	432.10M	569.23M	2.05B

BrightPath Biotherapeutics Co.Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 81.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Neutral. The current price of 81 is below the 20-day moving average (MA) of 81.05, above the 50-day MA of 67.50, and above the 200-day MA of 49.74, indicating a neutral trend. The MACD of 5.34 indicates Positive momentum. The RSI at 52.27 is Neutral, neither overbought nor oversold. The STOCH value of 12.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4594.

BrightPath Biotherapeutics Co.Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	71 Outperform	¥4.44B	17.18		―	9.47%	14.00%
4594	56 Neutral	¥9.02B	―		―	1254.76%	33.94%
2342	56 Neutral	¥3.85B	―		1.84%	5.00%	-458.79%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
4881	38 Underperform	¥4.66B	―		―	965.85%	-42.78%
4591	37 Underperform	¥5.34B	―		―	-59.53%	11.70%
4598	28 Underperform	¥6.94B	―		―	―	20.41%